RandrianarisoaEStefanNFritscheA. Periaortic adipose tissue compared with peribrachial adipose tissue mass as markers and possible modulators of cardiometabolic risk. Angiology. 2018;69(10):854–60.
2.
KatsikiNAthyrosVGMikhailidisDP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk?Curr Vasc Pharmacol. 2016;14(5):432–41.
3.
YounossiZMLoombaRRinellaME. Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology. 2018;68(1):361–71.
4.
AthyrosVGAlexandridesTKBilianouH. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. an expert panel statement. Metabolism. 2017;71:17–32.
5.
NerlekarNBrownAJMuthalalyRG. Association of epicardial adipose tissue and high-risk plaque characteristics: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(8). pii: e006379.
6.
PatelVBShahSVermaSOuditGY. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev. 2017;22(6):889–902.
7.
GoudisCAVasileiadisIELiuT. Epicardial adipose tissue and atrial fibrillation: pathophysiological mechanisms, clinical implications and potential therapies. Curr Med Res Opin. 2018:1–26.
8.
KatsikiNDoumasMMikhailidisDP. Lipids, statins and heart failure: an update. Curr Pharm Des. 2016;22:4796–806.
9.
WhayneTFJr. Epicardial fat thickness in heart failure and other clinical conditions. Angiology. 2013;64(3):169–72.
10.
AlnaebMEThompsonCSSeifalianAMHamiltonGMikhailidisDP. Regional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: a pilot study. In Vivo. 2007;21(6):1069–74.
11.
KitessaSMAbeywardenaMY. Lipid-Induced insulin resistance in skeletal muscle: the chase for the culprit goes from total intramuscular fat to lipid intermediates, and finally to species of lipid intermediates. Nutrients. 2016;8(8). pii: E466.
12.
Bielecka-DabrowaAFabisJMikhailidisDP. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci. 2018;39(4):331–53.
13.
NoelPPatelKDurgampudiC. Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections. Gut. 2016;65(1):100–11.
14.
GarciaTSRechTHLeitãoCB. Pancreatic size and fat content in diabetes: a systematic review and meta-analysis of imaging studies. PLoS One. 2017;12(7):e0180911.
15.
De PergolaGCampobassoNNardecchiaA. Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjects. BMC Cardiovasc Disord. 2015;15:108.
16.
KatsikiNPerez-MartinezPAnagnostisPMikhailidisDPKaragiannisA. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?Curr Vasc Pharmacol. 2018;16(3):219–27.
17.
SatoFMaedaNYamadaT. Association of epicardial, visceral, and subcutaneous fat with cardiometabolic diseases. Circ J. 2018;82(2):502–8.
18.
ParkJHParkYSKimYJ. Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound. 2010;18(4):121–6.
